Method of relieving symptoms of gastroesophageal reflux disease

Details Method of relieving symptoms of gastroesophageal reflux disease Method of relieving symptoms of gastroesophageal reflux disease

2006-07-24

2010-12-07

Spivack, Phyllis G. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S339000

Reexamination Certificate

active

07846921

ABSTRACT:
The invention relates to a method for relieving or ameliorating symptoms of gastroesophageal reflux disease by administering a medicament that includes the cholecystokin-2 (CCK-2) receptor antagonist itriglumide and a proton pump inhibitor (PPI).

REFERENCES:
patent: 93/12817 (1993-07-01), None
Hirschowitz, Bl, Yale J. Biol. Med., (Nov.-Dec. 1992), 65(6), 659-76.
Tougas, Prevalence and Impact of Upper Gastrointestinal Symptoms in the Canadian Population: Findings From the Digest Study, The American Journal of Gastroenterology, vol. 94, No. 10, 1999.
Dent, Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs, Gut, 2004.
Lassen, Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial, The Lancet, vol. 356, Aug. 5, 2000.
Vakil, Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease, Ailment Pharmacol Ther, vol. 19, pp. 1041-1049, 2004.
Crawley, How Satisfied Are Chronic Heartburn Sufferers with Their Prescription Medications? Results of the Patient Unmet Needs Survey, JCOM, vol. 7, No. 11, Nov. 2000.
Chiverton, Omeprazole (20 mg) daily given in the morning or evening; a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration, Ailment. Pharmacol. Therap., vol. 6, pp. 103-111, 1992.
Hatlebakk, Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily, Ailment Pharmacol Ther, vol. 12, pp. 1235-1240, 1998.
Katz, Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole, Ailment Pharmacol Ther, vol. 14, pp. 709-714, 2000.
Tytgat, Shortcomings of the first-generation proton pump inhibitors, European Journal of Gastroenterology & Hepatology, vol. 13 (suppl 1), pp. S29-S33, 2001.
Sachs, The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPase1,2, Annu. Rev. Pharmacol. Toxicol., vol. 35, pp. 277-305, 1995.
Sachs, Improving on PPI-based therapy of GORD, European Journal of Gastroenterology & Hepatology, vol. 13 (suppl 1), 2001.
Sachs, Current trends in the treatment of upper gastrointestinal disease, Best Practice & Research Clinical Gastroenterology, vol. 16, No. 6, pp. 835-849, 2002.
Wurst, Current Status of Acid Pump Antagonists (Reversible PPIs), Yale Journal of Biology and Medicine, vol. 69, pp. 233-243, 1996.
Maton, Drug Therapy: Omeprazole, The New England Journal of Medicine, vol. 324, No. 14, pp. 993-1004, 1991.
Noble, International Union of Pharmacology. XXI. Structure, Distribution, and Functions of Cholecystokinin Receptors, Pharmacological Reviews, vol. 51, No. 4, pp. 745-781, 1999.
Crawley, Biological Actions of Cholecystokinin, Peptides, vol. 15, No. 4, pp. 731-755, 1994.
Woodruff, Cholecystokinin Antagonists, Annu. Rev. Pharmacol. Toxicol., vol. 31, pp. 469-501, 1991.
Schubert, Neural, Hormonal, and Paracrine Regulation of Gastrin and Acid Secretion, The Yale Journal of Biology and Medicine, vol. 65, pp. 553-560, 1992.
Rehfeld, The Tumor Biology of Gastrin and Cholecystokinin, Advances in Cancer Research, vol. 63, pp. 295-347, 1994.
Gonzalez, Pharmacological and molecular characterization of muscular cholecystokinin receptors in the human lower oesophageal sphincter, Neruogastroenterol. Mot., vol. 12, pp. 539-546, 2000.
Enochs, Changes in protein and nucleic acid synthesis in rat gastric mucosa after pentagastrin, Am. J. Physiol., vol. 223, No. 2, pp. E223-E228, 1977.
Modlin, The Gastric Enterochromaffin-like Cell: An Enigmatic Cellular Link, Gastroenterology, vol. 111, pp. 783-810, 1996.
McGowan, Helicobacter pylori and Gastric Acid: Biological and Therapeutic Implications, Gastroenterology, vol. 110, pp. 926-938, 1996.
Makovec, Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCKB receptor antagonist, European Journal of Pharmacology, vol. 369, pp. 81-90, 1999.
Omura, Establishment of Surgically Induced Chronic Acid Reflux Esophagitis in Rats, Scand. J. Gastroenterol., vol. 34, pp. 948-953, 1999.
Richter, Efficacy and Safety of Esomeprazole Compared With Omeprazole in GERD Patients With Erosive Esophagitis: A Randomized Controlled Trial, The American Journal of Gastroenterology, vol. 96, No. 3, pp. 656-665, 2001.
Parson, M, “Novel approaches to the pharmacological blockade of gastric acid secretion”, Expert Opinion on Investigational Drugs, United Kingdom, vol. 14, No. 4, 2005, pp. 411-421.

Affiliated with

Also associated with

Rating

Method of relieving symptoms of gastroesophageal reflux disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of relieving symptoms of gastroesophageal reflux disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of relieving symptoms of gastroesophageal reflux disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4231974